GERMANTOWN, Md., Feb. 7, 2019 /PRNewswire/ -- Neuralstem,
Inc. (NASDAQ: CUR), a biopharmaceutical company focused on the
development of cell-based and small molecular therapeutic for
central nervous system indications, today announced the
initiation of a program to expand its current pipeline of
therapeutic products.
The strategic move comes on the heels of the appointment of
Kenneth C. Carter, Ph.D as Executive
Chairman. Carter previously served as the CEO of various
biopharmaceutical companies, including Avalon Pharmaceuticals and
Neximmune.
"Neuralstem is focused on the continued development of its
current technologies," said Carter. "However, we have engaged a
network of trusted experts and advisors to assist us in evaluating
new technologies. To date, this initiative has identified certain
preclinical and clinical stage assets that we believe, if
developed, could create significant value for shareholders while
expanding and diversifying our product pipeline."
Currently, the company has two technologies in Phase II clinical
trials - MSI-189, a small molecule for major depressive disorder
(MDD) and NSI 566, a stem cell therapy for Amyotrophic Lateral
Sclerosis (ALS).
For more information, please visit www.neuralstem.com/
About Neuralstem
Based in Germantown, Maryland, Neuralstem is a
clinical-stage biopharmaceutical company developing novel
treatments for nervous system diseases of high unmet medical need.
Neuralstem's diversified portfolio of product candidates includes
its proprietary neural stem cell technology.
The Company has two clinical stage candidates:
- NSI-566 is a neural stem cell therapy in clinical development
for treatment of paralysis in stroke, for Amyotrophic Lateral
Sclerosis (ALS) and for chronic spinal cord injury (cSCI).
- NSI-189 is a small molecule in clinical development for major
depressive disorder (MDD) and in preclinical development for
Angelman syndrome, irradiation-induced cognitive impairment, Type 1
and Type 2 diabetes, and stroke.
Cautionary Statement Regarding Forward Looking
Information
This news release contains "forward-looking statements" made
pursuant to the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. Such forward-looking statements
relate to future, not past, events and may often be identified by
words such as "expect," "anticipate," "intend," "plan," "believe,"
"seek" or "will." Forward-looking statements by their nature
address matters that are, to different degrees, uncertain. Specific
risks and uncertainties that could cause our actual results to
differ materially from those expressed in our forward-looking
statements include risks inherent in the development and
commercialization of potential products, uncertainty of clinical
trial results or regulatory approvals or clearances, need for
future capital, dependence upon collaborators and maintenance of
our intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking
statements. Additional information on potential factors that could
affect our results and other risks and uncertainties are detailed
from time to time in Neuralstem's periodic reports filed with the
Securities and Exchange Commission (SEC). We do not assume any
obligation to update any forward-looking statements.
Media Contact: investor@neuralstem.com
View original
content:http://www.prnewswire.com/news-releases/neuralstem-to-expand-pipeline-as-part-of-aggressive-growth-effort-300791445.html
SOURCE Neuralstem, Inc.
